{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045074","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2023-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.147624+00:00","generated_at":"2026-06-07T12:08:48.108174+00:00","sec_items":["1.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biofrontera enters payment addendum with affiliates; schedules ~$7.5M in payments through April 2024","bullets":["INC to pay Pharma $2.791M by Dec 20, 2023, reduced by ~$137K owed by Bioscience.","By Jan 31, 2024, INC owes Pharma ~$1.4-1.6M (DARM00429 remainder) and ~$2.9M under PO#11440.","By Jan 31, 2024, INC must pay AG invoice AR01207 and Bioscience invoices TAR01584 and TAR01593.","By Apr 30, 2024, INC pays 2023 purchase price variance and invoices for POs #11272, #11305, #11154.","Failure to timely pay Licensed Products constitutes material breach, triggering termination without cure period."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045074","json":"https://secwatch.observer/filing/0001493152-23-045074.json","markdown":"https://secwatch.observer/filing/0001493152-23-045074.md","text":"https://secwatch.observer/filing/0001493152-23-045074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223045074/0001493152-23-045074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223045074/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:08:48.108174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5cdbaa7a8b02a9a922495449e467d82979e3361","claim":"Biofrontera Inc. entered into Addendum to Amended and Restated License and Supply Agreement with Biofronter Pharma GmbH, Biofrontera Bioscience GmbH, and Biofrontera AG valued at Schedule of payments for purchase of Licensed Products through end of 2024 (effective 2023-12-12).","evidence_excerpt":"On December 12, 2023, Biofrontera Inc. (the “ Company ”) entered into an addendum (the “ Addendum ”) to its Amended and Restated License and Supply Agreement, dated as of June 16, 2021 (as amended on October 8, 2021, the “LSA”), by and among the Company, Biofrontera Pharma GmbH (“Pharma”), and Biofrontera Bioscience GmbH (“Bioscience”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223045074/0001493152-23-045074-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Biofronter Pharma GmbH, Biofrontera Bioscience GmbH, and Biofrontera AG"},{"label":"Value","value":"Schedule of payments for purchase of Licensed Products through end of 2024"},{"label":"Effective","value":"2023-12-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}